Use of inhaled anticholinergic agents in obstructive airway disease

Respiratory Care

Volumn 52, Issue 7, 2007, Pages 833-851

  Restrepo, Ruben D ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Anticholinergic; Antimuscarinic; Asthma; Chronic obstructive pulmonary disease; COPD; Ipratropium; Muscarinic receptor; Oxitropium; Tiotropium

Indexed keywords

ATROPINE; BA 679; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DOUVENT; FENOTEROL PLUS IPRATROPIUM BROMIDE; FORMOTEROL; GLUCOCORTICOID; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; IPRAVENT; LONG ACTING DRUG; OXITROPIUM BROMIDE; PLACEBO; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; STEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ANISOCORIA; ASTHMA; BLADDER OBSTRUCTION; BLURRED VISION; BRONCHODILATATION; BRONCHOSPASM; CHOLINERGIC TRANSMISSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COUGHING; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG COST; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEART ARREST; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART RATE; HUMAN; METERED DOSE INHALER; MICTURITION DISORDER; MONOTHERAPY; MYDRIASIS; PEAK EXPIRATORY FLOW; PROSTATE HYPERTROPHY; PULMONARY REHABILITATION; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT SECRETION; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; URINE RETENTION; XEROSTOMIA; CHEMISTRY; EVIDENCE BASED MEDICINE; INHALATIONAL DRUG ADMINISTRATION; REVIEW; UNITED STATES;

ADMINISTRATION, INHALATION; ASTHMA; CHOLINERGIC ANTAGONISTS; EVIDENCE-BASED MEDICINE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; UNITED STATES;

EID: 34548570729     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (207)

1. Gandevia B. Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders. Postgrad Med J 1975;51(Suppl 7):13-20.
2. Disse B, Reichl R, Speck G, Traunecker W, Ludwig Rominger KL, Hammer R. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci 1993;52(5-6):537-544.
3. Witek TJ Jr. The fate of inhaled drugs: the pharmacokinetics and pharmacodynamics of drugs administered by aerosol. Respir Care 2000;45(7):826-830.
4. Rau JL Jr. Anticholinergic (parasympatholytic) bronchodilators. In: Respiratory care pharmacology, 6th ed. St Louis: Mosby; 2002: 136-153.
5. Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Hardman JG, Limbard LE, editors. Goodman & Gilman's the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill; 1996:154-159.
6. Taylor DM, Auble TE, Calhoun WJ, Mosesso VN Jr. Current outpatient management of asthma shows poor compliance with International Consensus Guidelines. Chest 1999;116(6):1638-1645.
7. Meier CR, Jick H. Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK. Thorax 1997;52(7):612-617.
8. [No author listed]. PJ notice board (discontinued products). Pharm J 2004;272(7299):603.
9. Rang HP, Dale MM, Ritter JM, Gardner P. Pharmacology, 4th ed. Edinburgh, UK: Harcourt Publishers Ltd; 2001:110-138.
10. Pappanó AJ. Cholinoceptor-activating and cholinesterase inhibiting drugs. In: Katzung BG, editor. Basic and clinical pharmacology, 8th ed. New York: McGraw Hill; 2001:92-106.
11. 2 muscarinic receptor. Trends Pharmacol Sci 1998;19(8): 322-327.
12. Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease Am J Med 2004;117 Suppl 12A:24S-32S.
13. Gross NJ, Barnes PJ. A short tour around the muscarinic receptor. Am Rev Respir Dis 1988;138(4):765-767.
14. 3 receptors mediate contraction of human central and peripheral airway smooth muscle. Pulm Pharmacol 1990;3(1):47-51.
15. Lefkowitz RJ, Hoffman BB, Taylor P. Neurohormonal transmission: the autonomic and somatic motor nervous system. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. Elmsford, NY: Pergamon Press; 1990:84-121.
16. Joos GF. Potential usefulness of inhibiting neural mechanisms in asthma. Monaldi Arch Chest Dis 2000;55(5):411-414.
17. Barnes PJ. Modulation of neurotransmission in airways. Physiol Rev 1992;72(3):699-729.
18. Ayala LE, Ahmed T. Is there loss of protective muscarinic receptor mechanism in asthma? Chest 1989;96(6):1285-1291.
19. 2 muscarinic receptors in the lungs. Life Sci 1993;52(5-6):529-536.
20. Fryer AD, Jacoby DB. Parainfluenza virus infection damages inhibitory M2 muscarinic receptors on pulmonary parasympathetic nerves in the guinea-pig. Br J Pharmacol 1991;102(1):267-271.
21. 2 muscarinic receptor dysfunction. Am J Respir Crit Care Med 2003;167(4):550-556.
22. Gross NJ. Anticholinergic drugs. In: Barnes PJ, Grunstein MM, editors. Asthma. Philadelphia: Lippincott-Raven; 1997:1555-1568.
23. Beakes DE. The use of anticholinergics in asthma. J Asthma 1997; 34(5):357-368.
24. Gross NJ, Skorodin MS. Anticholinergic, antimuscarinic bronchodilators. Am Rev Respir Dis 1984;129(5):856-870.
25. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000;117(2 Suppl):63S-66S.
26. Gross NJ, Petty TL, Friedman M, Skorodin MS, Silvers GW, Donohue JF. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease: a three-center study. Am Rev Respir Dis 1989;139(5):1188-1191.
27. Minette A, Marcq M. Oxitropium bromide (Ba 253), an advance in the field of anticholinergic bronchodilating treatments: preliminary results. Rev Inst Hyg Mines (Hasselt) 1979;34(3):115-123.
28. Flohr E, Bischoff KO. Oxitropium bromide, a new anticholinergic drug, in a dose-response and placebo comparison in obstructive airway diseases. Respiration 1979;38(2):98-104.
29. Frith PA, Jenner B, Dangerfield R, Atkinson J, Drennan C. Oxitropium bromide. Dose-response and time-response study of a new anticholinergic bronchodilator drug. Chest 1986;89(2):249-253.
30. Frith PA, Jenner B, Atkinson J. Effects of inhaled oxitropium and fenoterol, alone and in combination, in chronic airflow obstruction. Respiration 1986;50 Suppl 2:294-297.
31. Nakano Y, Enomoto N, Kawamoto A, Hirai R, Chida K. Efficacy of adding multiple doses of oxitropium bromide to salbutamol delivered by means of a metered-dose inhaler with a spacer device in adults with acute severe asthma. J Allergy Clin Immunol 2000;106(3):472-478.
32. Cazzola M, Matera MG, Di Perna F, Calderaro F, Califano C, Vinciguerra A. A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease. Respir Med 1998;92(2):354-357.
33. Haddad EB. Mak JC, Barnes PJ. Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol 1994;45(5):899-907.
34. O'Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996;154(4 Pt 1):876-880.
35. Barnes PJ. Tiotropium bromide. Expert Opin Investig Drugs 2001; 10(4):733-740.
36. Maesen FP, Smeets JJ, Sledsens TJ, Wald FD, Cornelissen PJ. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group, Eur Respir J 1995; 8(9):1506-1513.
37. Witek TJ Jr. Anticholinergic bronchodilators. Respir Care Clin N Am 1999;5(4):521-536.
38. Takahashi T, Belvisi MG, Patel H, Ward JK, Tadjkarimi S, Yacoub MH, Barnes PJ. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 1994;150(6 Pt 1):1640-1645.
39. Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, Witek TJ Jr. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161(4 Pt 1):1136-1142.
40. Gross NJ. Tiotropium bromide. Chest 2004;126(6):1946-1953.
41. Casaburi R, Mahler DA, Jones PW, Wanner A, San Pedro G, Zu-Wallack RL, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19(2):217-224.
42. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, Cornelissen PJ; Dutch/Belgium Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 2002;19(2):209-216.
43. Colice GL. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. Am J Med 1996;100(1A):11S-18S.
44. Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedman M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD: a retrospective analysis of data from seven clinical trials. Chest 1996;110(1):62-70.
45. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest 1994;105(5):1411- 1419.
46. The COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997;112(6):1514-1521.
47. Friedman M. A multicenter study of nebulized bronchodilator solutions in chronic obstructive pulmonary disease. Am J Med 1996;100(1A):30S-39S.
48. Gross N, Tashkin D, Miller R, Oren J, Coleman W, Linberg S. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. Respiration 1998;65(5):354-362.
49. Hodzhev B, Kostianev S, Todorov I, Belev G, Kartev S. Individual results of treatment of COPD with low doses of fenoterol compared with treatment with ipratropium bromide. Folia Med (Plovdiv) 1999;41(4):46-52.
50. 2 agonists in patients with chronic obstructive pulmonary disease. Am J Med 1996;100(1A): 40S-48S.
51. Tashkin DP, Ashutosh K, Bleecker ER, Britt EJ, Cugell DW, Cummisky JM, et al. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-center study. Am J Med 1986;81(5A):81-90.
52. Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch Intern Med 1999;159(2):156-160.
53. 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006 Apr 19;(2):CD001387.
54. 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006 July 19;(3):CD006101.
55. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115(4):957-965.
56. 2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163(5):1087-1092.
57. SMS40314. A multicenter, randomized, double-blind, double-dummy, parallel-group, 8-week comparison of salmeterol xinafoate versus ipratropium bromide versus salmeterol xinafoate plus ipratropium bromide versus placebo in subjects with chronic obstructive pulmonary disease. [Internet]. Updated Sept 21, 2005. http://ctr.gsk.co.uk/Summary/salmeterol/IV_SMS40314.pdf. (Last accessed April 19, 2007)
58. SMS40315. A multicenter, randomized, double-blind, double-dummy, parallel group, 8-week comparison of salmeterol xinafoate versus ipratropium bromide versus salmeterol xinafoate plus ipratropium bromide versus placebo in subjects with chronic obstructive pulmonary disease. [Internet]. Updated Sept 7, 2005. http://ctr.gsk.co.uk/Summary/salmeterol/IV_SMS40315.pdf. (Last accessed April 19, 2007)
59. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, et al; Formoterol in Chronic Obstructive Pulmonary Disease I Study Group. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164(5):778-784.
60. Stahl E, Wadbo M, Bengtsson T, Strom K, Lofdahl C-G. Health-related quality of life, symptoms, exercise capacity and lung function during treatment for moderate to severe COPD. J Drug Assess 2002;5:81-94.
61. van Noord JA, de Munck DR, Bantje TA, Hop WCJ, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000;15(5):878-885.
62. Yildiz F, Basyigit I, Yildirim E, Boyaci H, Ilgazli A. Different bronchodilator combinations have similar effects on health status in COPD. Pulm Pharamacol Ther 2006;19(2):101-106.
63. Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006;61(10):854-862. (Erratum in: Thorax 2007;62(2):191.)
64. Briggs DD Jr, Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther 2005;18(6):397-404.
65. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58(5):399-404. (Erratum in: Thorax 2005;60(2):105.)
66. Niewoehner D, Rice K, Cote C, Paulson D, Cooper JA, Korducki L, et al . Reduced COPD exacerbations and associated health care utilization with once-daily tiotropium (TIO) in the VA medical system (abstract). Am J Respir Crit Care Med 2004;169:A207.
67. Niewoehner D, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143(5):317-326.
68. Beeh KM, Beier J, Buhl R, Stark-Lorenzen P, Gerken F, Metzdorf N; ATEM-Studiengruppe. [Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities.] Pneumologie 2006;60(6):341-346. (article in German)
69. Dusser D, Bravo M-L, Iacono P, on behalf of the MISTRAL Study Group. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006;27(3):547-555. (Erratum in: Eur Respir J 2006;27(5):1076.)
70. Verkindre C, Bart F, Aguilaniu B, Fortin F, Guerin JC, Le Merre C, et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006;73(4):420-427.
71. O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23(6):832-840.
72. Rodrigo GJ, Nannini LJ. Tiotropium for the treatment of stable chronic pulmonary disease: a systematic review with meta-analysis. Pulm Pharmacol Ther 2006 Mar 2; [Epub ahead of print]
73. Lindsay M, Lee A, Chan K, Poon P, Han LK, Wong WC, Wong S. Does pulmonary rehabilitation give additional benefit over tiotropium therapy in primary care management of chronic obstructive pulmonary disease? Randomized controlled clinical trial in Hong Kong Chinese. J Clin Pharm Ther 2005;30(6):567-573.
74. Moayyedi P, Congleton J, Page RL, Pearson SB, Muers MF. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 1995;50(8):834-837.
75. Patrick DM, Dales RE, Stark RM, Laliberte G, Dickinson G. Severe exacerbations of COPD and asthma: incremental benefit of adding ipratropium to usual therapy. Chest 1990;98(2):295-297.
76. Rebuck AS, Chapman KR, Abboud R, Pare PD, Kreisman H, Wolkove N, Vickerson F. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med 1987;82(1)1:59-64.
77. 2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002;(4):CD003900.
78. Celli BR, MacNeeW; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23(6):932-946. (Erratum in: Eur Respir J 2006;27(1):242.)
79. GOLD. The Global Initiative For Chronic Obstructive Lung Disease, 2006. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2006 update. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute.
80. Backman R, Hellstrom PE. Fenoterol and ipratropium in respiratory treatment of patients with chronic bronchitis. Curr Ther Res Clin Exper 1985;38(1):135-140.
81. Cydulka RK, Emerman CL. Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1995;25(4):470-473.
82. Karpel JP, Pesin J, Greenberg D, Gentry E. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990;98(4):835-839.
83. Lloberes P, Ramis L, Montserrat JM, Serra J, Campistol J, Picado C, Agusti-Vidal A. Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. Eur Respir J 1988;1(6):536-539.
84. O'Driscoll BR, Taylor RJ, Horsley MG, Chambers DK, Bernstein A. Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction. Lancet 1989;1(8652):1418-1420.
85. Shrestha M, O'Brien T, Haddox R, Gourlay HS, Reed G. Decreased duration of emergency department treatment of chronic obstructive pulmonary disease exacerbations with the addition of ipratropium bromide to beta-agonist therapy. Ann Emerg Med 1991;20(11):1206-1209.
86. Fernandes LB, Goldie RG. The single mediator approach to asthma therapy: is it so unreasonable? Curr Opin Phamacol 2003;3(3):251-256.
87. Rodrigo GJ, Rodrigo C. Triple inhaled drug protocol for the treatment of acute severe asthma. Chest 2003;123(6):1908-1915.
88. Parker AL. Airway reactivity is a determinant of bronchodilator responsiveness after methacholine-induced bronchoconstriction. J Asthma 2004;41(6):671-677.
89. O'Connor BJ. Combination therapy. Pulm Pharmacol Ther 1998;11(5-6):397-399.
90. Cazzola M, Centanni S, Donner CF. Anticholinergic agents. Pulm Pharmacol Ther 1998;11(5-6):381-392.
91. Ruffin RE, Fitzgerald JD, Rebuck AS. A comparison of the bronchodilator activity of Sch 1000 and salbutamol. J Allergy Clin Immunol 1977;59(2):136-141.
92. Connolly MJ. Ageing, late-onset asthma and the beta-adrenoceptor. Pharmacol Ther 1993;60(3):389-404.
93. Ullah MI, Newman GB, Saunders KB. Influence of age on response to ipratropium and salbutamol in asthma. Thorax 1981;36(7):523-529.
94. Boulet L-P, Becker A, Bérubé D, Beveridge R, Ernst P. Summary of recommendations from the Canadian Asthma Consensus Report 1999. CMAJ 1999;161(11 Suppl):S1-S12.
95. Chhabra S, Pandey KK. Comparison of acute bronchodilator effects of inhaled ipratropium bromide and salbutamol in bronchial asthma. J Asthma 2002;39(5):375-381.
96. Partridge MR, Saunders KB. Site of action of ipratropium bromide and clinical and physiological determinants of response in patients with asthma. Thorax 1981;36(7):530-533.
97. Jolobe OM. Asthma vs. non-specific reversible airflow obstruction: clinical features and responsiveness to anticholinergic drugs. Respiration 1984;45(3):237-242.
98. Emilien G, Maloteaux J-M. Current therapeutic uses and potential of β-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol 1998;53(6):389-404.
99. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326(8):501-506.
100. 2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000;162(1):75-80.
101. 2-adrenoceptor polymorphism. Thorax 2000;55(9): 762-767.
102. 2 adrenoreceptor genotype predisposes to exacerbations in young asthmaticus taking regular salmeterol. Thorax 2006;61(11):940-944.
103. Israel E, Chinchilli VM, Ford JG, Boushey HA, Chemiack RM, Craig TJ, et al: National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004;364(9444):1505-1512.
104. van Schayck CP, Dompeling E, van Herwaarden CLA, Folgering H, Akkermans RP, van den Broek PJJA, van Weel C. Continuous and on demand use of bronchodilators in patients with non-steroid dependent asthma and chronic bronchitis: four-year follow-up randomized controlled study. Br J Gen Pract 1995;45(394):239-244.
105. Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev 2006;(4):CD003269.
106. Pierce RJ Holmes PW Campbell AH. Use of ipratropium bromide in patients with severe airways obstruction. Aust N Z J Med 1982;12(1):38-43.
107. Tammivaara R, Elo J, Mansury L. Terbutaline controlled-release tablets and ipratropium aerosol in nocturnal asthma. Allergy 1993;48(1):45-48.
108. Mazzei JA, Torres J. Blind randomized cross-over comparative study of salbutamol and the combination fenoterol-ipratropium IK6 in patients with bronchial asthma. Respiration 1986;50 Suppl 2:313-317.
109. Macaluso S, Del Torre L. Efficacy and compliance to prolonged Duovent treatment of bronchospasm; comparison with salbutamol. Respiration 1986;50 Suppl 2:222-225.
110. Wolstenholme RJ, Shettar SP. Comparison of a combination of fenoterol with ipratropium bromide (Duovent) and salbutamol in young adults with nocturnal asthma. Respiration 1989;55(3):152-157.
111. Haahtela T, Ahokas I, Ahonen A, van Assendelft A, Havu M, Havu K, et al. Inhaled bronchodilators in asthma: low or high dose? Ann Allergy 1991;66(2):175-180.
112. Waite DA. Comparison of Duovent with salbutamol in chronic asthmatics: a long term study in community practice. Postgrad Med J 1987;63(Suppl 1):4s.
113. Philip-Joet F, Reynaud-Gaubert M, Jirou-Najou JL, Arnaud A. Comparison of Berodual and salbutamol in asthma: a multicenter evaluation. Respiration 1990;57(6):379-383.
114. Colice GL, Carnathan B, Sung J, Paramore LC. A respiratory therapist-directed protocol for managing inpatients with asthma and COPD incorporating a long-acting bronchodilator. J Asthma 2005;42(1):29-34.
115. Gosens R, Bos IST, Zaagsma J, Meurs H. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med 2005;171(10):1096-1102.
116. Gosens R, Zaaqsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res 2006 May 9;7:73.
117. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma: from bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000;161(5):1720-1745.
118. Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167(3):418-424.
119. British Medical Association. Asthma: a follow up statement from an international paediatric asthma consensus group. Arch Dis Child 1992;67(2):240-248.
120. Mitchell EA. Consensus on acute asthma management in children. Ad Hoc Paediatric Group. N Z Med J 1992;105(941):353-355.
121. Rachelefsky GS, Warner JO. International consensus on the management of pediatric asthma: a summary statement. Pediatr Pulmonol 1993;15(2):125-127.
122. Warner JO, Gotz M, Landau LI, Levison H, Milner AD, Pedersen S, Silverman M. Management of asthma: a consensus statement. Arch Dis Child 1989;64(7):1065-1079.
123. Scarfone RJ, Fuchs SM, Nager AL, Shane SA. Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. Pediatrics 1993;92(4):513-518.
124. Tal A, Levy N, Bearman JE. Methylprednisolone therapy for acute asthma in infants and toddlers: a controlled clinical trial. Pediatrics 1990;86(3):350-356.
125. Sears MR. Clinical application of β-agonists. Pract Allergy Immunol 1992;7:98-100.
126. 2-adrenergic agonist for use in asthma: pharmacology, pharmokinetics, clinical efficacy and adverse effects. Pharmacotherapy 1985;5(3):109-126.
127. Chapman KR. An international perspective on anticholinergic therapy. Am J Med 1996;100(1A):2S-4S.
128. Gross NJ. Ipratropium bromide. N Engl J Med 1988;319(8):486-494.
129. Silverman M. The role of anticholinergic antimuscarinic bronchodilator therapy in children. Lung 1990;168 Suppl:304-309.
130. Hargreave FE, Dolovich J, Newhouse MT. The assessment and treatment of asthma: a conference report. J Allergy Clin Immunol 1990;85(6):1098-1111.
131. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Revised edition, November 2005. [Internet]. Available at http://www.sign.ac.uk. (Accessed February 6, 2007)
132. Ducharme FM, Davis GM. Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the treatment of mild and moderate acute asthma. J Pediatr 1998;133(4):479-485.
133. 2-adrenergic medication in acute asthma attack? J Investig Allergol Clin Immunol 1998;8(1):30-34.
134. Cook JJ, Fergusson DM, Dawson KP. Ipratropium and fenoterol in the treatment of acute asthma. Pharmatherapeutica 1985;4(6):383-386.
135. Qureshi F, Pestian J, Davis P, Zaritsky A. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med 1998;339(15):1030-1035.
136. Beck R, Robertson C, Galdes-Sebaldt M, Levison H. Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma. J Pediatr 1985;107(4):605-608.
137. Phanichyakarn P, Kraisarin C, Sasisakulporn C. Comparison of inhaled terbutaline and inhaled terbutaline plus ipratropium bromide in acute asthmatic children. Asian Pac J Allergy Immunol 1990;8(1):45-48.
138. Schuh S, Johnson DW, Callahan S, Canny G, Levison H. Efficacy of frequent nebulized ipratropium bromide added to frequent highdose albuterol therapy in severe childhood asthma. J Pediatr 1995; 126(4):639-645.
139. Watanasomsiri A, Phipatanakul W. Comparison of nebulized ipratropium bromide with salbutamol vs salbutamol alone in acute asthma exacerbation in children. Ann Allergy Asthma Immunol 2006;96(5):701-706.
140. Watson WTA, Becker AB, Simmons FER. Comparison of ipratropium solution, fenoterol solution, and their combination administered by nebulizer and face mask to children with acute asthma. J Allergy Clin Immunol 1988;82(6):1012-1018.
141. Reisman J, Galdes-Sebaldt M, Kazim F, Canny G, Levison H. Frequent administration by inhalation of salbutamol and ipratropium bromide in the initial management of severe acute asthma in children. J Allergy Clin Immunol 1988;81(1):16-20.
142. Qureshi F, Zaritsky A, Lakkis H. Efficacy of nebulized ipratropium in severely asthmatic children. Ann Emerg Med 1997;29(2):205-211.
143. Zorc JJ, Pusic MV, Ogborn CJ, Lebet R, Duggan AK. Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics 1999;103(4 Pt 1):748-752.
144. Osmond MH, Klassen TP. Efficacy of ipratropium bromide in acute childhood asthma: a meta-analysis. Acad Emerg Med 1995;2(7):651-656.
145. Guill MF, Maloney MJ, DuRant RH. Comparison of inhaled metaproterenol, inhaled atropine sulfate, and their combination in treatment of children with acute asthma. Ann Allergy 1987;59(5):367-371.
146. McDonald NJ, Bara AI, McKean M. Anticholinergic therapy for chronic asthma in children over two years of age. Cochrane Database Syst Rev 2003(1):CD003535.
147. 2-adrenoceptor agonists in childhood asthma. Eur J Respir Dis 1986;68(4):239-247.
148. Freeman J, Landau LI. The effects of ipratropium bromide and fenoterol nebulizer solutions in children with asthma. Clin Pediatr (Phila) 1989;28(12):556-560.
149. Hutchison AA, Olinsky A, Landau LI. Long term atropine in chronic severe childhood asthma. Aust Paediatr J 1980;16(4):267-269.
150. Mann NP, Hiller EJ. Ipratropium bromide in children with asthma. Thorax 1982;37(1):72-74.
151. Sly PD, Landau LI, Olinsky A. Failure of ipratropium bromide to modify the diurnal variation of asthma in asthmatic children. Thorax 1987;42(5):357-360.
152. Raes M, Mulder P, Kerrebijn KF. Long-term effect of ipratropium bromide and fenoterol on the bronchial hyperresponsiveness to histamine in children with asthma. J Allergy Clin Immunol 1989;84(6 Pt 1):874-879.
153. Vazquez C, Fidalgo I, Virto MC, Labayru MT, Casas C. [Effectiveness of disodium cromoglycate, salbutamol, and ipratropium bromide in the inhibition of exercise-induced bronchospasm.] An Esp Pediatr 1984;20(8):756-762. (article in Spanish)
154. Zimmermann T, Drexel W. [Bronchial asthma in childhood: therapy with fenoterol and ipratropium bromide powder.] Monatsschr Kinderheilkd 1984;132(12):915-917. (article in German)
155. Henry RL, Hiller EJ, Milner AD, Hodges IG, Stokes GM. Nebulised ipratropium bromide and sodium cromoglycate in the first two years of life. Arch Dis Child 1984;59(1):54-57.
156. Naspitz CK, Sole D. Treatment of acute wheezing and dyspnea attacks in children under 2 years old: inhalation of fenoterol plus ipratropium bromide versus fenoterol. J Asthma 1992;29(4):253-258.
157. Schuh S, Johnson D, Canny G, Reisman J, Shields M, Kovesi T, et al. Efficacy of adding nebulized ipratropium bromide to nebulized albuterol therapy in acute bronchiolitis. Pediatrics 1992;90(6):920-923.
158. Wang EE, Milner R, Allen U, Maj H. Bronchodilators for treatment of mild bronchiolitis: a factorial randomised trial. Arch Dis Child 1992;67(3):289-293.
159. Mallol J, Barrueto L, Girardi G, Munoz R, Puppo H, Ulloa V, et al. Use of nebulized bronchodilators in infants under 1 year of age: analysis of four forms of therapy. Pediatr Pulmonol 1987;3(5):298-303.
160. Mallol J, Barrueto L, Girardi G, Toro O. Bronchodilator effect of fenoterol and ipratropium bromide in infants with acute wheezing: use of MDI with a spacer device. Pediatr Pulmonol 1987;3(5):352-356.
161. Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due due to emphysema. N Engl J Med 1984;311(7):421-425.
162. Gross NJ, Skorodin MS. Anticholinergic, antimuscarinic bronchodilators. Am Rev Respir Dis 1984;129(5):856-870.
163. Iosson N. Images in clinical medicine: nebulizer-associated anisocoria. N Engl J Med 2006;354(9):e8.
164. Brodie T, Adalat S. Unilateral fixed dilated pupil in a well child. Arch Dis Child 2006;91(12):961.
165. Weir RE, Whitehead DE, Zaidi FH, Greaves BB. Pupil blown by a puffer. Lancet 2004;363(9424):1853.
166. Weckerle PE, Voykov B. [Pupillary disorder after use of asthma spray aerosol.] Klin Monatsbl Augenheilkd 2005;222(5):437-439. (article in German)
167. Papalkar D, Sharma NS, Ooi JL, Sharma S, Francis IC. Pupil blown by a puffer (letter). Lancet 2004;364(9432):415.
168. Goldstein JB, Biousse V, Newman NJ. Unilateral pharmacologic mydriasis in a patient with respiratory compromise (letter). Arch Ophthalmol 1997;115(6):806.
169. Kizer KM, Bess DT, Bedford NK. Blurred vision from ipratropium bromide inhalation (letter). Am J Health Syst Pharm 1999;56(9):914.
170. Kizer KM, Bess DT, Bedford NK. Blurred vision from ipratropium bromide inhalation (letter). Am J Health Syst Pharm 2000;57(10):996.
171. Ryan CA. Ipratropium bromide induced unilateral mydriasis (letter). Ir Med J 1997;90(2):76.
172. Ryan CA. Styrofoam cup, ipratropium bromide, and anisocoria (letter). Clin Pediatr (Phila) 1999;38(5):318.
173. Geraerts SD, Plotz FB, van Goor C, Duval EL, van Vught H. Unilateral fixed dilated pupil in a ventilated child with asthma. Eur J Emerg Med 2000;7(3):247-248.
174. Openshaw H. Unilateral mydriasis from ipratropium in transplant patients. Neurology 2006;67(5):914.
175. Bond DW, Vyas H, Venning HE. Mydriasis due to self-administered inhaled ipratropium bromide (letter). Eur J Pediatr 2002;161(3):178.
176. Jannun DR, Mickel SF. Anisocoria and aerosolized anticholinergics. Chest 1986;90(1):148-149.
177. Tuohy PG. Ipratropium and the eye (letter). N Z Med J 1989;102(872):386.
178. Helprin GA, Clarke GM. Unilateral fixed dilated pupil associated with nebulised ipratropium bromide (letter). Lancet 1986;2(8521-8522):1469.
179. Lust K, Livingstone I. Nebulizer-induced anisocoria (letter). Ann Intern Med 1998;128(4):327.
180. Bisquerra RA, Botz GH, Nates JL. Ipratropium-bromide-induced acute
181. Karpel JP, Pesin J, Greenberg D, Gentry E. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990;98(4):835-839.
182. Beasley R, Fishwick D, Miles JF, Hendeles L. Preservatives in nebulizer solutions: risks without benefit. Pharmacotherapy 1998;18(1):130-139.
183. Boucher M, Roy MT, Henderson J. Possible association of benzalkonium chloride in nebulizer solutions with respiratory arrest. Ann Pharmacother 1992;26(6):772-774.
184. Bellia V, Ferrara G, Cibella F, Cuttitta G, Visconti A, Insalaco G, et al. Comparison of the effect of oxitropium bromide and of slow-release theophylline on nocturnal asthma. Postgrad Med J 1988;64(754):583-586.
185. Kreisman H, Frank H, Wolkove N, Gent M. Synergism between ipratropium and theophylline in asthma. Thorax 1981;36(5):387-391.
186. Ahonen A, Alanko K, Mattson K. Bronchodilator action of two different doses of ipratropium bromide (SCH 1000) compared with fenoterol and placebo. Curr Ther Res Clin Exper 1978;24:65.
187. Salorinne Y, Ahonen A. Comparison of the bronchodilator effect of ipratropium bromide powder and two doses of ipratropium bromide aerosol in the treatment of asthma. Curr Ther Res Clin Exper 1988;24:1073.
188. Anthonisen NR, Connett JE, Enright PL, Manfreda J; and the Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002;166(3):333-339.
189. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006;130(6):1695-1703.
190. Keam SJ, Keating GM. Tiotropium bromide: a review of its use as maintenance therapy in patients with COPD. Treat Respir Med 2004;3(4):247-268.
191. Hogan TJ, Geddes R, Gonzalez ER. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease. Clin Ther 2003;25(1):285-297.
192. Friedman M, Menjoge SS, Anton SF, Kesten S. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics 2004;22(11):741-749.
193. Commonwealth of Australia. Schedule of Pharmaceutical Benefits Effective from May 2001; GENERAL Respiratory system. [Internet]. www.pbs.gov.au/ publications/2004/2004-05-01-generalschedule.pdf.
194. Oostenbrink JB, Rutten-van Molken MP, Al MJ, Van Noord JA, Vincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004;23(2):241-249.
195. Garcia Ruiz AJ, Leiva Fernandez F, Martos Crespo F. [Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol.] Arch Bronconeumol 2005;41(5):242-248. (article in Spanish)
196. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004;23(5):698-702.
197. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59 Suppl 1:1-232.
198. D'Urzo AD, De Salvo MC, Ramirez-Rivera A, Almeida J, Sichletidis L, Rapatz G, Kottakis J; FOR-INT-03 Study Grop. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 2001;119(5):1347-1356.
199. O'Donnell DE, Berley JC, Chau LK, Webb KA. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med 1997;155(1):109-115.
200. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158(5 Pt 1):1557-1565.
201. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160(2):542-549.
202. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153(3):967-975.
203. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146(8):545-555.
204. Decramer M, Celli B, Tashkin DP, Pauwels RA, Burkhart D, Cassino C, Kesten S. Clinical trial design considerations in assessing longterm functional impacts of tiotropium in COPD: the UPLIFT trial COPD 2004;1(2):303-312.
205. Khan KS, Daya S, Jahad AR. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 1996;156(6):661-666.
206. Asthma in children under five years of age. The General Practitioner in Asthma Group, the British Association of Accident and Emergency Medicine, the British Paediatric Respiratory Society and the Royal College of Paediatrics and Child Health. Thorax 1997;52 Suppl 1:S9-S10; S18-S21.
207. Everard ML, Bara A, Kurian M, Elliott TM, Ducharme F, Mayowe V. Anticholinergic drugs for wheeze in children under the age of two years. Cochrane Database Syst Rev 2005;3:CD001279.